NCT03995017View on ClinicalTrials.gov

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 9, 2020

Primary Completion Date

October 19, 2022

Study Completion Date

December 31, 2024

Conditions
Esophagus Cancer, AdenocarcinomaStomach Cancer, Adenocarcinoma
Interventions
DRUG

Rucaparib

Rucaparib tablet

DRUG

Ramucirumab

Ramucirumab intravenous solution

DRUG

Nivolumab

Nivolumab intravenous solution

Trial Locations (8)

60637

University of Chicago Medical Center, Chicago

64064

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64154

University of Kansas Cancer Center - North, Kansas City

66112

University of Kansas Cancer Center - West, Kansas City

66205

KU Cancer Center, Fairway

University of Kansas Cancer Center - CRC, Fairway

The University of Kansas Cancer Center, Westwood Campus, Kansas City

66210

University of Kansas Cancer Center - Overland Park, Overland Park

Sponsors
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Clovis Oncology, Inc.

INDUSTRY

lead

University of Kansas Medical Center

OTHER